Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226847 · ClinicalTrials.gov registry record · NA
Pulmonary Vein Isolation in Athletes
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03226847 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 10 participants.
The verdict
NCT03226847, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Pulmonary vein isolation (PVI) has become a common and effective treatment for paroxysmal and persistent atrial fibrillation (AF), particularly in patients with drug-refractory disease. Intense endurance exercise is a known risk factor for atrial fibrillation. In general, these athletes poorly tolerate most common antiarrhythmic drugs used for atrial fibrillation control and often PVI is recommended for durable management. While the efficacy of PVI in athletes is similar to the general AF population, some athletes with lone atrial fibrillation report a reduction in subjective exertional capacity following PVI, despite maintenance of sinus rhythm and absence of pulmonary vein stenosis on imaging. The investigators hypothesize that PVI may alter pulmonary vein function and affect peak exercise performance. The investigators propose a small, prospective study of endurance athletes undergoing antral PVI for treatment of lone atrial fibrillation. Peak metabolic performance and pulmonary vein function will be assessed pre- and post-PVI by metabolic stress testing and cardiac MRI, respectively.
Interventions
- PROCEDURE Pulmonary Vein Isolation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2021-03-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226847
The ClinicalTrials.gov registry entry for NCT03226847 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pulmonary Vein Isolation is the first listed.
NCT03226847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226847 about?
NCT03226847 is a clinical study titled "Pulmonary Vein Isolation in Athletes". Pulmonary vein isolation (PVI) has become a common and effective treatment for paroxysmal and persistent atrial fibrillation (AF), particularly in patients with drug-refractory disease. Intense endurance exercise is a known risk factor for atrial fibrillation. In general, these athletes poorly toler...
What is the current status of trial NCT03226847?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-07-17. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT03226847?
The interventions under investigation include: Pulmonary Vein Isolation (PROCEDURE).
Who is sponsoring clinical trial NCT03226847?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.